date,title,source
Oct-26-18,Data from Clinical and Pre-Clinical Trials Evaluating Verona Pharmas RPL554 in Cystic Fibrosis Presented at North American Cystic Fibrosis Conference,GlobeNewswire
Oct-30-18,"Verona Pharma to Announce Interim Results for Nine Months Ended September 30, 2018 and Provide Clinical Development Update",GlobeNewswire
Oct-31-18,Verona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment,GlobeNewswire
Nov-06-18,"Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2018",GlobeNewswire
Dec-17-18,Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD,GlobeNewswire
